N-methyl-N-(3-pyridinylcarbonyl)glycine | 926217-00-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-methyl-N-(3-pyridinylcarbonyl)glycine
• 英文别名: 2-[Methyl(3-pyridinylcarbonyl)amino]acetic acid；2-[methyl(pyridine-3-carbonyl)amino]acetic acid
• CAS: 926217-00-7
• 化学式: C₉H₁₀N₂O₃
• 分子量: 194.19
• InChiKey: BBUQZKNNYGFMHF-UHFFFAOYSA-N

物化性质

• 沸点：
  426.4±25.0 °C(Predicted)
• 密度：
  1.302±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  70.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  N-methyl-N-(3-pyridinylcarbonyl)glycine 、 丁炔二酸二甲酯 在 乙酸酐 作用下， 反应 0.08h， 以34%的产率得到1-methyl-2-(3-pyridinyl)-1H-pyrrole-3,4-dicarboxylic acid dimethyl ester
  参考文献：
  名称：

  Microwave-assisted synthesis of pyridylpyrroles from N-acylated amino acids

  摘要：

  A small library of 3- and 4-pyridyl-substituted pyrroles was prepared from N-acylated amino acids. Nicotinoyl or isonicotinoyl chloride was used for the N-acylation of benzyl esters of amino acids. Debenzylation by palladium-catalyzed hydrogenation gave N-acylated amino acids. Dehydration of the acylated amino acids gave cyclic intermediates, manchnones or aziactones, which were treated in situ with alkynes in 1,3-dipolar cycloadditions. The starting materials were prepared in a parallel fashion, and microwave irradiation was used to facilitate the cycloaddition reactions. The regiochemistry of the cycloaddition was studied. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.09.094
• 作为产物：
  描述：

  N-methyl-N-(3-pyridinylcarbonyl)glycine phenylmethyl ester 在 palladium 10% on activated carbon 、 氢气 作用下， 以 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 5.0h， 以99%的产率得到N-methyl-N-(3-pyridinylcarbonyl)glycine
  参考文献：
  名称：

  Microwave-assisted synthesis of pyridylpyrroles from N-acylated amino acids

  摘要：

  A small library of 3- and 4-pyridyl-substituted pyrroles was prepared from N-acylated amino acids. Nicotinoyl or isonicotinoyl chloride was used for the N-acylation of benzyl esters of amino acids. Debenzylation by palladium-catalyzed hydrogenation gave N-acylated amino acids. Dehydration of the acylated amino acids gave cyclic intermediates, manchnones or aziactones, which were treated in situ with alkynes in 1,3-dipolar cycloadditions. The starting materials were prepared in a parallel fashion, and microwave irradiation was used to facilitate the cycloaddition reactions. The regiochemistry of the cycloaddition was studied. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tet.2009.09.094

文献信息

• Non-Flushing Niacin Analogues, and Methods of Use Thereof
  申请人：Bachovchin William W.

  公开号：US20090312355A1

  公开（公告）日：2009-12-17

  One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

  本发明的一个方面涉及取代吡啶及其药学上可接受的盐，对一系列哺乳动物疾病具有活性。本发明的另一个方面涉及一种制药组合物，包括本发明的化合物或其药学上可接受的盐，以及药学上可接受的载体。本发明还涉及治疗一系列哺乳动物疾病或病症的方法，包括但不限于高脂血症、高胆固醇血症、动脉粥样硬化、冠状动脉疾病、充血性心力衰竭、心血管疾病、高血压、冠心病、心绞痛、糙皮病、哈特努普综合征、类癌综合征、动脉闭塞性疾病、肥胖症、甲状腺功能减退症、血管收缩、骨关节炎、类风湿性关节炎、糖尿病、阿尔茨海默病、脂肪萎缩症或血脂异常，提高血清高密度脂蛋白（HDL）水平，降低血清低密度脂蛋白（LDL）水平。
• NON-FLUSHING NIACIN ANALOGUES, AND METHODS OF USE THEREOF
  申请人：Trustees of Tufts College

  公开号：US20160151343A1

  公开（公告）日：2016-06-02

  One aspect of the present invention relates to substituted pyridines and pharmaceutically acceptable salts thereof that are active against a range of mammalian maladies. Another aspect of the invention relates to a pharmaceutical composition, comprising a compound of the present invention or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable excipient. The present invention also relates to methods of treating a range of mammalian maladies or conditions, including but not limited to hyperlipidemia, hypercholesterolemia, atherosclerosis, coronary artery disease, congestive heart failure, cardiovascular disease, hypertension, coronary heart disease, angina, pellagra, Hartnup's syndrome, carcinoid syndrome, arterial occlusive disease, obesity, hypothyroidism, vasoconstriction, osteoarthritis, rheumatoid arthritis, diabetes, Alzheimer's disease, lipodystrophy, or dyslipidemia, raising serum high-density lipoprotein (HDL) levels, and lowering serum low-density lipoprotein (LDL) levels.

  本发明的一个方面涉及取代吡啶及其药学上可接受的盐，对多种哺乳动物疾病具有活性。本发明的另一个方面涉及一种制药组合物，包括本发明的化合物或其药学上可接受的盐；以及药学上可接受的赋形剂。本发明还涉及治疗多种哺乳动物疾病或症状的方法，包括但不限于高脂血症、高胆固醇血症、动脉粥样硬化、冠状动脉疾病、充血性心力衰竭、心血管疾病、高血压、冠心病、心绞痛、糙皮病、哈特努普综合症、类癌综合症、动脉闭塞性疾病、肥胖症、甲状腺功能减退症、血管收缩、骨关节炎、类风湿性关节炎、糖尿病、阿尔茨海默病、脂肪萎缩症或血脂异常，提高血清高密度脂蛋白（HDL）水平，降低血清低密度脂蛋白（LDL）水平。
• WRINKLE-PREVENTIVE/AMELIORATING AGENT
  申请人：SHISEIDO COMPANY, LTD.

  公开号：EP1908454A1

  公开（公告）日：2008-04-09

  A wrinkle-preventing and -improving composition comprising one or more than one compound selected from the group consisting of α-amino acid derivatives represented by the following general formula (1) and salts thereof: wherein, R1 represents hydrogen atom, CH3 group or CH2OH group, R2 and R3 each independently represent hydrogen atom, alkyl group having 1 to 4 carbons, provided that R2 and R3 cannot be hydrogen atom at the same time, or R2 and R3 together with N atom to which they are bound may form a ring structure having a total carbon number of 4 to 6, in which case said ring structure may optionally contain an oxygen atom as a heteroatom, R4 represents hydrogen atom, alkyl group having 1 to 18 carbons, wherein when R1 and R4 are hydrogen atom, it cannot be that one of R2 and R3 is benzyloxycarbonyl group and the other is hydrogen atom.

  一种防皱和改善皱纹的组合物，包含一种或一种以上选自下式（1）所代表的 α-氨基酸衍生物及其盐类的化合物： 其中，R1 代表氢原子、CH3 基团或 CH2OH 基团，R2 和 R3 各自独立地代表氢原子、具有 1 至 4 个碳原子的烷基，但 R2 和 R3 不能同时为氢原子，或者 R2 和 R3 与它们所结合的 N 原子可形成一个总碳数为 4 至 6 的环结构、R4 代表氢原子或碳原子数为 1 至 18 的烷基，其中当 R1 和 R4 为氢原子时，R2 和 R3 不能一个为苄氧羰基，另一个为氢原子。
• WRINKLE-PREVENTING AND IMPROVING COMPOSITION
  申请人：TSUNENAGA Makoto

  公开号：US20100168468A1

  公开（公告）日：2010-07-01

  A wrinkle-preventing and -improving composition comprising one or more than one compound selected from the group consisting of α-amino acid derivatives represented by the following general formula (1) and salts thereof: wherein, R 1 represents hydrogen atom, CH 3 group or CH 2 OH group, R 2 and R 3 each independently represent hydrogen atom, alkyl group having 1 to 4 carbons, provided that R 2 and R 3 cannot be hydrogen atom at the same time, or R 2 and R 3 together with N atom to which they are bound may form a ring structure having a total carbon number of 4 to 6, in which case said ring structure may optionally contain an oxygen atom as a heteroatom, R 4 represents hydrogen atom, alkyl group having 1 to 18 carbons, wherein when R 1 and R 4 are hydrogen atom, it cannot be that one of R 2 and R 3 is benzyloxycarbonyl group and the other is hydrogen atom.
• Wrinkle-preventing and improving composition
  申请人：Tsunenaga Makoto

  公开号：US20110065794A1

  公开（公告）日：2011-03-17

  A wrinkle-preventing and -improving composition comprising one or more than one compound selected from the group consisting of α-amino acid derivatives represented by the following general formula (1) and salts thereof: wherein, R 1 represents hydrogen atom, CH 3 group or CH 2 OH group, R 2 and R 3 each independently represent hydrogen atom, alkyl group having 1 to 4 carbons, provided that R 2 and R 3 cannot be hydrogen atom at the same time, or R 2 and R 3 together with N atom to which they are bound may form a ring structure having a total carbon number of 4 to 6, in which case said ring structure may optionally contain an oxygen atom as a heteroatom, R 4 represents hydrogen atom, alkyl group having 1 to 18 carbons, wherein when R 1 and R 4 are hydrogen atom, it cannot be that one of R 2 and R 3 is benzyloxycarbonyl group and the other is hydrogen atom.